Research published in Lancet Respiratory Medicine shows that benralizumab, a monoclonal antibody, significantly reduces asthma attacks and COPD exacerbations compared to prednisolone. This is the first new treatment for these conditions in 50 years, with experts believing it could be a game-changer. Benralizumab could benefit those with severe asthma or COPD, as it has shown promising results in reducing symptoms. The study’s lead investigator, Mona Bafadhel, believes this treatment has the potential to improve the lives of many individuals suffering from these respiratory conditions.
Source link
Sixty seconds on . . . asthma injections
